USE OF PDE-5 INHIBITORS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS TREATING PULMONARY HYPERTENSION

摘要

This invention relates to the use of certain cyclic guanosine 3 , 5 -monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension.